COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
In an exclusive interview, pathologist Frederick (Fritz) Kiechle, MD, PhD, reviews biomarker changes and related clinical laboratory testing at different disease stages of COVID-19.
Joel Lefferts, PhD, of the Geisel School of Medicine at Dartmouth and Clinical Genomics and Advanced Technology (CGAT) at Dartmouth-Hitchcock Medical Center (DHMC), explains how SARS-CoV-2 virus genome sequencing and tracking the variants will complement contact tracing.
CDC continues to change SARS-CoV-2 diagnostic testing guidance.
What the open source protocol means to COVID-19 testing laboratories.
What happened with Ohio Gov. Mike DeWine’s coronavirus test.
In an exclusive interview, Dr. Joel Lefferts, a genomics specialist at Dartmouth’s Geisel School of Medicine, discusses coronavirus research around sequencing a small subset of the SARS-CoV-2 virus.
In an exclusive interview, pathologist Frederick (Fritz) Kiechle, MD, PhD, reviews biomarker changes and related clinical laboratory testing at different disease stages of COVID-19.
Joel Lefferts, PhD, of the Geisel School of Medicine at Dartmouth and Clinical Genomics and Advanced Technology (CGAT) at Dartmouth-Hitchcock Medical Center (DHMC), explains how SARS-CoV-2 virus genome sequencing and tracking the variants will complement contact tracing.
CDC continues to change SARS-CoV-2 diagnostic testing guidance.
What the open source protocol means to COVID-19 testing laboratories.
What happened with Ohio Gov. Mike DeWine’s coronavirus test.
In an exclusive interview, Dr. Joel Lefferts, a genomics specialist at Dartmouth’s Geisel School of Medicine, discusses coronavirus research around sequencing a small subset of the SARS-CoV-2 virus.
